Výsledky vyhľadávania - "Cetuximab/administration & dosage"

Survival Without Quality of Life Deterioration in the GORTEC 2014-04 'OMET' Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR

Autori: Juliette Thariat Mathieu Bosset Antoine Falcoz a ďalší

Prispievatelia: Juliette Thariat Mathieu Bosset Antoine Falcoz a ďalší

Zdroj: International journal of radiation oncology, biology, physics, vol. 121, no. 5, pp. 1194-1206

Predmety: Humans, Quality of Life, Radiosurgery/methods, Radiosurgery/mortality, Male, Female, Middle Aged, Head and Neck Neoplasms/mortality, Head and Neck Neoplasms/pathology, Head and Neck Neoplasms/therapy, Head and Neck Neoplasms/radiotherapy, Head and Neck Neoplasms/drug therapy, Aged, Neoplasm Metastasis, Cetuximab/administration & dosage, Cetuximab/therapeutic use, Fluorouracil/administration & dosage, Squamous Cell Carcinoma of Head and Neck/mortality, Squamous Cell Carcinoma of Head and Neck/therapy, Squamous Cell Carcinoma of Head and Neck/secondary, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Adult, Survival Rate

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39612953
https://serval.unil.ch/resource/serval:BIB_F3A45574859E.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_F3A45574859E1
https://serval.unil.ch/notice/serval:BIB_F3A45574859E

Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial

Autori: Guigay, Joël Le Caer, Hervé Ferrand, François-Régis a ďalší

Prispievatelia: Guigay, Joël Le Caer, Hervé Ferrand, François-Régis a ďalší

Zdroj: The lancet. Healthy longevity, vol. 5, no. 6, pp. e392-e405

Predmety: Male, Aged, 80 and over, Squamous Cell Carcinoma of Head and Neck, Cetuximab, [SDV.CAN]Life Sciences [q-bio]/Cancer, Humans, Aged, Female, Squamous Cell Carcinoma of Head and Neck/drug therapy, Squamous Cell Carcinoma of Head and Neck/pathology, Head and Neck Neoplasms/drug therapy, Head and Neck Neoplasms/pathology, Neoplasm Recurrence, Local/drug therapy, Neoplasm Recurrence, Local/pathology, Fluorouracil/administration & dosage, Fluorouracil/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Carboplatin/administration & dosage, Carboplatin/therapeutic use, Carboplatin/adverse effects, Cetuximab/administration & dosage, Cetuximab/therapeutic use, Cetuximab/adverse effects, Carboplatin, 3. Good health, [SDV.CAN] Life Sciences [q-bio]/Cancer, Head and Neck Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Fluorouracil, Neoplasm Recurrence, Local

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38759667
https://u-picardie.hal.science/hal-04578230v1
https://doi.org/10.1016/s2666-7568(24)00048-5
https://u-picardie.hal.science/hal-04578230v1/document
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_FC7E3ACA49E02
https://serval.unil.ch/notice/serval:BIB_FC7E3ACA49E0
https://serval.unil.ch/resource/serval:BIB_FC7E3ACA49E0.P001/REF.pdf

Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08).

Autori: Ruhstaller, T. Thuss-Patience, P. Hayoz, S. a ďalší

Prispievatelia: Ruhstaller, T. Thuss-Patience, P. Hayoz, S. a ďalší

Predmety: Adenocarcinoma/pathology, Adenocarcinoma/therapy, Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carcinoma, Squamous Cell/pathology, Squamous Cell/therapy, Cetuximab/administration & dosage, Chemoradiotherapy/mortality, Cisplatin/administration & dosage, Combined Modality Therapy, Docetaxel/administration & dosage, Esophageal Neoplasms/pathology, Esophageal Neoplasms/therapy, Esophagectomy/mortality, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoadjuvant Therapy/mortality, Prognosis, Prospective Studies, Survival Rate

Relation: Annals of Oncology; https://iris.unil.ch/handle/iris/75284; serval:BIB_187C909027A6; 000438508100013

Dostupnosť: https://iris.unil.ch/handle/iris/75284
https://doi.org/10.1093/annonc/mdy105

Multicenter Randomized Double-Blind, Placebo-Controlled Trial GORTEC (Groupe Oncologie Radiotherapie Tete et Cou) 2009-01 Evaluating the Effect of the Regenerating Agent on Radiodermatitis of Head and Neck Cancer Patients.

Autori: Tao, Y. Auperin, A. Sire, C. a ďalší

Predmety: Administration, Topical, Adult, Aged, 80 and over, Antineoplastic Agents, Immunological/administration & dosage, Cetuximab/administration & dosage, Dermatologic Agents/administration & dosage, Dose Fractionation, Radiation, Female, Glycosaminoglycans/administration & dosage, Head and Neck Neoplasms/radiotherapy, Humans, Male, Middle Aged, Protective Agents/administration & dosage, Radiation-Protective Agents/administration & dosage, Radiodermatitis/drug therapy, Radiodermatitis/prevention & control

Relation: International Journal of Radiation Oncology - Biology - Physics; https://iris.unil.ch/handle/iris/60436; serval:BIB_4C686C881374; 000411225300018

Dostupnosť: https://iris.unil.ch/handle/iris/60436
https://doi.org/10.1016/j.ijrobp.2017.07.019

Randomized trial comparing two methods of re-irradiation after salvage surgery in head and neck squamous cell carcinoma: Once daily split-course radiotherapy with concomitant chemotherapy or twice daily radiotherapy with cetuximab.

Autori: Tao, Y. Faivre, L. Laprie, A. a ďalší

Predmety: Adult, Aged, Carcinoma, Squamous Cell/mortality, Squamous Cell/therapy, Cetuximab/administration & dosage, Chemoradiotherapy, Female, Head and Neck Neoplasms/mortality, Head and Neck Neoplasms/therapy, Humans, Male, Middle Aged, Neoplasm Recurrence, Local/therapy, Re-Irradiation/methods, Salvage Therapy, Squamous Cell Carcinoma of Head and Neck, Cetuximab, Head and neck squamous cell carcinoma, Hyperfractionation, Re-irradiation, Recurrent or second primary

Relation: Radiotherapy & Oncology; https://iris.unil.ch/handle/iris/207370; serval:BIB_820BB085FC44; 000444505600011

Dostupnosť: https://iris.unil.ch/handle/iris/207370
https://doi.org/10.1016/j.radonc.2018.05.005

A PET-based nomogram for oropharyngeal cancers.

Autori: Castelli, J. Depeursinge, A. Ndoh, V. a ďalší

Predmety: Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carboplatin/administration & dosage, Cetuximab/administration & dosage, Chemoradiotherapy/methods, Cisplatin/administration & dosage, Female, Humans, Male, Middle Aged, Neoplasm Staging, Nomograms, Oropharyngeal Neoplasms/diagnostic imaging, Oropharyngeal Neoplasms/therapy, Positron Emission Tomography Computed Tomography/methods, Prognosis, Radiotherapy, Intensity-Modulated/methods, Young Adult, Nomogram, Oropharyngeal cancer, PET, Prognostic score

Relation: European Journal of Cancer; https://iris.unil.ch/handle/iris/148529; serval:BIB_CF335D446D50; 000399856400029

Dostupnosť: https://iris.unil.ch/handle/iris/148529
https://doi.org/10.1016/j.ejca.2017.01.018

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

Autori: Kopetz, S. Grothey, A. Yaeger, R. a ďalší

Prispievatelia: Kopetz, S. Grothey, A. Yaeger, R. a ďalší

Zdroj: RiUVic. Repositori institucional de la UVic-UCC
instname
Kopetz, S, Grothey, A, Yaeger, R, Van Cutsem, E, Desai, J, Yoshino, T, Wasan, H, Ciardiello, F, Loupakis, F, Hong, Y S, Steeghs, N, Guren, T K, Arkenau, H T, Garcia-Alfonso, P, Pfeiffer, P, Orlov, S, Lonardi, S, Elez, E, Kim, T W, Schellens, J H M, Guo, C, Krishnan, A, Dekervel, J, Morris, V, Ferrandiz, A C, Tarpgaard, L S, Braun, M, Gollerkeri, A, Keir, C, Maharry, K, Pickard, M, Christy-Bittel, J, Anderson, L, Sandor, V & Tabernero, J 2019, ' Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer ', New England Journal of Medicine, vol. 381, no. 17, pp. 1632-1643 . https://doi.org/10.1056/NEJMoa1908075

Predmety: Male, IRINOTECAN, Cetuximab, Kaplan-Meier Estimate, TRAMETINIB, VEMURAFENIB, THERAPY, 0302 clinical medicine, Medicaments -- Assaigs clínics, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Benzimidazoles/administration & dosage, Treatments in Oncology, 11 Medical and Health Sciences, Aged, 80 and over, Sulfonamides, COLON-CANCER, Colorectal Neoplasms/drug therapy, Middle Aged, DABRAFENIB, Intention to Treat Analysis, 3. Good health, Còlon -- Càncer, Disease Progression, Female, Colorectal Neoplasms, Life Sciences & Biomedicine, PROGRESSION-FREE SURVIVAL, Adult, Proto-Oncogene Proteins B-raf, Irinotecan/therapeutic use, INHIBITION, Irinotecan, 03 medical and health sciences, Medicine, General & Internal, Carbamates/administration & dosage, General & Internal Medicine, Proto-Oncogene Proteins B-raf/genetics, Humans, Cetuximab/administration & dosage, Aged, Colorectal Cancer, Sulfonamides/administration & dosage, Science & Technology, 42 Health sciences, MUTATIONS, Antineoplastic Combined Chemotherapy Protocols/adverse effects, 32 Biomedical and clinical sciences, Survival Analysis, Mutation, Benzimidazoles, Carbamates, Electrocorticography, ACQUIRED-RESISTANCE

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/31566309
https://pubmed.ncbi.nlm.nih.gov/31566309/
https://portal.findresearcher.sdu.dk/da/publications/encorafenib-binimetinib-and-cetuximab-in-braf-v600emutated-colore
https://mdanderson.elsevierpure.com/en/publications/encorafenib-binimetinib-and-cetuximab-in-braf-v600emutated-colore
https://www.nejm.org/doi/full/10.1056/NEJMoa1908075
https://www.ncbi.nlm.nih.gov/pubmed/31566309
https://www.nejm.org/doi/suppl/10.1056/NEJMoa1908075/suppl_file/nejmoa1908075_appendix.pdf
https://lirias.kuleuven.be/handle/123456789/642210
https://doi.org/10.1056/nejmoa1908075
https://findresearcher.sdu.dk:8443/ws/files/158747483/nejmoa1908075.pdf
https://discovery-pp.ucl.ac.uk/id/eprint/10086190/

Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)

Autori: Curioni-Fontecedro, Alessandra Perentes, Jean Yannis Gelpke, Hans a ďalší

Prispievatelia: Curioni-Fontecedro, Alessandra Perentes, Jean Yannis Gelpke, Hans a ďalší

Zdroj: Br J Cancer
British Journal of Cancer, Vol. 120, No 10 (2019) pp. 968-974
British journal of cancer, vol. 120, no. 10, pp. 968-974

Predmety: Adult, Male, 10255 Clinic for Thoracic Surgery, Cetuximab, 610 Medicine & health, Docetaxel, Article, 03 medical and health sciences, 0302 clinical medicine, Aged, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/pathology, Carcinoma, Non-Small-Cell Lung/radiotherapy, Carcinoma, Non-Small-Cell Lung/surgery, Cetuximab/administration & dosage, Cetuximab/adverse effects, Chemoradiotherapy, Cisplatin/administration & dosage, Cisplatin/adverse effects, Docetaxel/administration & dosage, Docetaxel/adverse effects, Female, Humans, Middle Aged, Neoadjuvant Therapy/adverse effects, Neoplasm Staging, Progression-Free Survival, Carcinoma, Non-Small-Cell Lung, 1306 Cancer Research, ddc:616, Neoadjuvant Therapy, 3. Good health, 10032 Clinic for Oncology and Hematology, 2730 Oncology, Cisplatin

Popis súboru: application/pdf; 41416_2019_Article_447.pdf - application/pdf

Prístupová URL adresa: https://www.nature.com/articles/s41416-019-0447-0.pdf
https://pubmed.ncbi.nlm.nih.gov/30988393
https://www.nature.com/articles/s41416-019-0447-0.pdf
https://europepmc.org/article/MED/30988393
https://www.zora.uzh.ch/id/eprint/175170/1/41416_2019_Article_447.pdf
https://www.nature.com/articles/s41416-019-0447-0
https://www.zora.uzh.ch/id/eprint/175170/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734655
https://archive-ouverte.unige.ch/unige:155813
https://doi.org/10.1038/s41416-019-0447-0
https://archive-ouverte.unige.ch/unige:155813
https://serval.unil.ch/resource/serval:BIB_6DA91E6BDAAE.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_6DA91E6BDAAE
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_6DA91E6BDAAE4
https://www.zora.uzh.ch/id/eprint/175170/
https://doi.org/10.5167/uzh-175170

PEG tube dependency after prophylactic placement in 209 head and neck cancer patients treated with chemoradiotherapy or radiation with cetuximab

Autori: Lucia B. Vrolijk Camiel L. M. de Roij van Zuijdewijn Marije Slingerland a ďalší

Zdroj: Clinical Otolaryngology. 44:172-175

Predmety: Gastrostomy, Male, Cetuximab, Antineoplastic Agents, Head and Neck Neoplasms/drug therapy, Chemoradiotherapy, Gastrostomy/adverse effects, Middle Aged, Enteral Nutrition/adverse effects, 03 medical and health sciences, Antineoplastic Agents, Immunological, Enteral Nutrition, 0302 clinical medicine, Immunological/administration & dosage, Head and Neck Neoplasms, Humans, Female, Cetuximab/administration & dosage, Aged, Retrospective Studies

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/30615256
https://research.vumc.nl/en/publications/peg-tube-dependency-after-prophylactic-placement-in-209-head-and-
https://onlinelibrary.wiley.com/doi/full/10.1111/coa.13282
https://www.ncbi.nlm.nih.gov/pubmed/30615256
https://www.narcis.nl/publication/RecordID/oai%3Ascholarlypublications.universiteitleiden.nl%3Aitem_2988090
https://pubmed.ncbi.nlm.nih.gov/30615256/
https://hdl.handle.net/1887/122872

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Autori: Ezra E W Cohen Denis Soulières Christophe Le Tourneau a ďalší

Prispievatelia: Ezra E W Cohen Denis Soulières Christophe Le Tourneau a ďalší

Zdroj: The Lancet, Vol. 393, No 10167 (2019) pp. 156-167
Lancet, Vol. 393, no. 10167, p. 156-167 (2019)

Predmety: Neoplasm recurrence, Male, Kaplan-Meier estimate, Antineoplastic combined chemotherapy protocols - administration & dosage, Cetuximab - adverse effects, Head and neck neoplasms - drug therapy, monoclonal, Cetuximab, Docetaxel - administration & dosage, Docetaxel, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized, Antibodies, Squamous cell carcinoma of head and neck - drug therapy, Drug Administration Schedule, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Humans, Methotrexate - administration & dosage, Middle aged, Humanized, humanized - administration & dosage, Aged, ddc:616, Disease progression, Squamous Cell Carcinoma of Head and Neck, Drug administration schedule, Head and neck neoplasms - pathology, Squamous cell carcinoma of head and neck - pathology, humanized - therapeutic use, Middle Aged, Squamous cell carcinoma of head and neck - secondary, 3. Good health, Neoplasm Recurrence, Methotrexate, Local, Antineoplastic combined chemotherapy protocols - therapeutic use, local - drug therapy, Antineoplastic combined chemotherapy protocols - adverse effects, Head and Neck Neoplasms, KEYNOTE-040 investigators, Disease Progression, Methotrexate - adverse effects, Female, Neoplasm Recurrence, Local, Cetuximab - administration & dosage, Docetaxel - adverse effects

Popis súboru: application/pdf; Print-Electronic

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/30509740
https://www.ncbi.nlm.nih.gov/pubmed/30509740
https://europepmc.org/article/MED/30509740
https://koreauniv.pure.elsevier.com/en/publications/pembrolizumab-versus-methotrexate-docetaxel-or-cetuximab-for-recu
https://www.sciencedirect.com/science/article/abs/pii/S0140673618319998
https://pubmed.ncbi.nlm.nih.gov/30509740/
https://jhu.pure.elsevier.com/en/publications/pembrolizumab-versus-methotrexate-docetaxel-or-cetuximab-for-recu
https://archive-ouverte.unige.ch/unige:155811
https://hdl.handle.net/2078.1/212774

Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial

Autori: Sclafani, F Kim, TY Cunningham, D a ďalší

Prispievatelia: Sclafani, F Kim, TY Cunningham, D a ďalší

Zdroj: International Journal of Cancer. 140:431-439

Predmety: Male, Cetuximab, Colorectal Neoplasms / genetics, 0302 clinical medicine, KRAS exon 2 mutation, cetuximab, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Camptothecin / analogs & derivatives, Insulin-Like Growth Factor I, Exons / genetics, Humanized, Insulin-Like Growth Factor I / genetics, Antibodies, Monoclonal, Exons, Middle Aged, Colorectal Neoplasms / drug therapy, IGF Type 1 / genetics, 3. Good health, IGF-2, Mutation / genetics, IGF-1, Female, Insulin-Like Growth Factor II / genetics, Colorectal Neoplasms, Receptor, Adult, Cetuximab / administration & dosage, Antibodies, Monoclonal, Humanized, Irinotecan, Antibodies, Disease-Free Survival, Proto-Oncogene Proteins p21(ras), 03 medical and health sciences, Double-Blind Method, Insulin-Like Growth Factor II, Antineoplastic Combined Chemotherapy Protocols / therapeutic use, Humans, IGF Type 1, Proto-Oncogene Proteins p21(ras) / genetics, chemorefractory colorectal cancer, Humanized / therapeutic use, Aged, dalotuzumab, EREG, Monoclonal / therapeutic use, Mutation, Camptothecin, Camptothecin / administration & dosage, IGF-1R

Popis súboru: Print-Electronic; application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/27681944
https://onlinelibrary.wiley.com/doi/10.1002/ijc.30453
https://europepmc.org/article/MED/27681944
https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.30453
https://mdanderson.elsevierpure.com/en/publications/dalotuzumab-in-chemorefractory-kras-exon-2-mutant-colorectal-canc
https://repository.icr.ac.uk/handle/internal/785
https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/30930

Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy

Autori: Spindler, Karen-Lise Garm Pallisgaard, Niels Appelt, Ane Lindegaard a ďalší

Zdroj: Spindler, K-L G, Pallisgaard, N, Appelt, A L, Andersen, R F, Schou, J V, Nielsen, D, Pfeiffer, P, Yilmaz, M, Johansen, J S, Hoegdall, E V, Jakobsen, A & Jensen, B V 2015, 'Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy', European Journal of Cancer, vol. 51, no. 17, pp. 2678-2685. https://doi.org/10.1016/j.ejca.2015.06.118
Spindler, K-L G, Pallisgaard, N, Appelt, A L, Andersen, R F, Schou, J V, Nielsen, D, Pfeiffer, P, Yilmaz, M, Johansen, J S, Hoegdall, E V, Jakobsen, A & Jensen, B V 2015, ' Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy ', European journal of cancer (Oxford, England : 1990), vol. 51, no. 17, pp. 2678-2685 . https://doi.org/10.1016/j.ejca.2015.06.118

Predmety: Adult, Male, Tissue Fixation, Camptothecin/administration & dosage, Paraffin Embedding/methods, DNA, Neoplasm/blood, Cetuximab, Kaplan-Meier Estimate, Irinotecan, Proto-Oncogene Proteins p21(ras), Proto-Oncogene Proteins p21(ras)/genetics, Outcome Assessment (Health Care), 03 medical and health sciences, 0302 clinical medicine, ErbB Receptors/antagonists & inhibitors, Antineoplastic Combined Chemotherapy Protocols, Outcome Assessment, Health Care, 80 and over, Humans, Prospective Studies, Neoplasm Metastasis, Cetuximab/administration & dosage, Proportional Hazards Models, Aged, Aged, 80 and over, Paraffin Embedding, Epidermal Growth Factor, Colorectal Neoplasms/drug therapy, DNA, DNA, Neoplasm, Outcome Assessment (Health Care)/methods, Middle Aged, Prognosis, 3. Good health, ErbB Receptors, Multivariate Analysis, Mutation, Neoplasm, Tissue Fixation/methods, Camptothecin, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Colorectal Neoplasms, Receptor

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/26508156
https://vbn.aau.dk/da/publications/38b8feb0-f48e-42b8-b68f-af70943943f9
https://doi.org/10.1016/j.ejca.2015.06.118
https://www.forskningsdatabasen.dk/en/catalog/2467026601
https://europepmc.org/abstract/MED/26508156
https://vbn.aau.dk/da/publications/clinical-utility-of-kras-status-in-circulating-plasma-dna-compare
https://pubmed.ncbi.nlm.nih.gov/26508156/
https://www.sciencedirect.com/science/article/abs/pii/S0959804915006449
https://forskning.ruc.dk/da/publications/clinical-utility-of-kras-status-in-circulating-plasma-dna-compare
https://portal.findresearcher.sdu.dk/da/publications/60370d82-9df5-476e-ada1-d13d9d28152f
https://doi.org/10.1016/j.ejca.2015.06.118
https://portal.findresearcher.sdu.dk/da/publications/60370d82-9df5-476e-ada1-d13d9d28152f
https://pure.au.dk/portal/en/publications/6842427f-e76a-42ef-b4a2-ae83794e621d
https://doi.org/10.1016/j.ejca.2015.06.118

A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG)

Autori: Degirmencioglu S Tanriverdi O Menekse S a ďalší

Zdroj: Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 24(1)

Predmety: Male, Lung Neoplasms, intestine perforation, Turkey, retrospective study, diarrhea, Pooled Analysis, Cetuximab, thrombocytopenia, medical record review, fluorouracil, 0302 clinical medicine, middle aged, Antineoplastic Combined Chemotherapy Protocols, genetics, malignant hypertension, cancer survival, disease free survival, Braf-Mutation, Aged, 80 and over, progression free survival, adult, Panitumumab, Liver Neoplasms, clinical trial, Prognosis, Folfox4, anemia, 3. Good health, Bevacizumab, Survival Rate, aged, survival rate, liver tumor, folinic acid, bevacizumab, blood transfusion, cancer prognosis, Article, deep vein thrombosis, Proto-Oncogene Proteins p21(ras), 03 medical and health sciences, colorectal carcinoma, turkey (bird), cancer combination chemotherapy, neutropenia, Humans, human, Aged, Retrospective Studies, cancer immunotherapy, protein p21, oxaliplatin, nail disease, dehydration, KRAS protein, Adult, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Bevacizumab/administration & dosage, Cetuximab/administration & dosage, Colorectal Neoplasms/*drug therapy/genetics/pathology, Female, Follow-Up Studies, Liver Neoplasms/*drug therapy/genetics/secondary, Lung Neoplasms/*drug therapy/genetics/secondary, Middle Aged, Mutation, Panitumumab/administration & dosage, Proto-Oncogene Proteins p21(ras)/*genetics, Colorectal cancer, major clinical study, infection, drug efficacy, multicenter study, nausea and vomiting, neuropathy, observational study, prognosis, proteinuria, mutation, colorectal tumor, drug safety, KRAS protein, human, very elderly, Leucovorin, rash, lung tumor, cetuximab, Plus Irinotecan, irinotecan, antineoplastic agent, metastatic colorectal cancer, female, Metastatic, mucosa inflammation, Fluorouracil, secondary, Colorectal Neoplasms, lung embolism, ileus, epistaxis, overall survival, tumor localization, heart arrhythmia, male, acute kidney failure, KRAS, Chemotherapy, follow up, controlled study, Colorectal Cancer, constipation, hand foot syndrome, K ras protein, febrile neutropenia, Kras, pathology, panitumumab

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/30941962
https://avesis.yyu.edu.tr/publication/details/2691f661-6a65-4364-a1ee-aa7479a4ba21/oai
https://avesis.yyu.edu.tr/publication/details/6e7976cd-0cc7-4df7-9db1-60baf793a782/oai
https://hdl.handle.net/11499/30529
https://hdl.handle.net/20.500.14551/19050

Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer

Autori: Spindler, Karen Lise Garm Demuth, Christina Sorensen, Boe Sandahl a ďalší

Zdroj: Spindler, K L G, Demuth, C, Sorensen, B S, Johansen, J S, Nielsen, D, Pallisgaard, N, Hoegdall, E, Pfeiffer, P & Vittrup Jensen, B 2018, 'Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer', Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, vol. 40, no. 11. https://doi.org/10.1177/1010428318811207

Predmety: Cell-free DNA plasma, metastatic colorectal cancer, prognosis, Cell-Free Nucleic Acids/analysis, Follow-Up Studies, Humans, Middle Aged, Carcinoembryonic Antigen/metabolism, Male, Case-Control Studies, Young Adult, Biomarkers, Tumor/analysis, Liver Neoplasms/drug therapy, Aged, 80 and over, Adult, Female, Irinotecan/administration & dosage, Cetuximab/administration & dosage, Survival Rate, Colorectal Neoplasms/drug therapy, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Adolescent, Denmark, C-Reactive Protein/metabolism, Everolimus/administration & dosage, Cohort Studies

Popis súboru: application/pdf

Dostupnosť: https://portal.findresearcher.sdu.dk/da/publications/32403c14-b4e8-4ad5-b30d-8d6ed9b19b9e
https://doi.org/10.1177/1010428318811207
https://findresearcher.sdu.dk/ws/files/144505973/Total_cell_free_DNA_carcinoembryonic_antigen_and_C_reactive_protein_for_assessment_of_prognosis_in_patients_with_metastatic_colorectal_cancer.pdf

Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer.

Autori: Bourhis, J. Stein, A. Paul de Boer, J. a ďalší

Predmety: Antibodies, Monoclonal, Humanized/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Cetuximab/administration & dosage, Clinical Trials as Topic, Humans, Neoplasms/drug therapy, Neoplasms/pathology, Prognosis, Anti–PD-L1, Avelumab, Cetuximab, Combination therapy, anti-EGFR

Relation: Cancer Treatment Reviews; https://iris.unil.ch/handle/iris/208943; serval:BIB_90CC642BEF44; 000654999300003

Dostupnosť: https://iris.unil.ch/handle/iris/208943
https://doi.org/10.1016/j.ctrv.2021.102172

Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE

Autori: Suton, Petar Skelin, Marko Rakušić, Zoran a ďalší

Predmety: Adult, Male, Antineoplastic Agents / administration & dosage, Oropharyngeal Neoplasms / therapy, Cetuximab / administration & dosage, Squamous Cell Carcinoma of Head and Neck / therapy, Chemoradiotherapy, Oropharyngeal Neoplasms / mortality, Middle Aged, Survival Analysis, Odds Ratio, Humans, Squamous Cell Carcinoma of Head and Neck / virology, Female, Oropharyngeal Neoplasms / virology, Squamous Cell Carcinoma of Head and Neck / mortality, Cisplatin / administration & dosage, Papillomaviridae, Neoplasm Recurrence, Local / epidemiology, Aged

Popis súboru: application/pdf

Prístupová URL adresa: https://urn.nsk.hr/urn:nbn:hr:105:503286

Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer

Autori: Spindler, Karen-Lise Garm Demuth, Christina Sorensen, Boe Sandahl a ďalší

Zdroj: Spindler , K-L G , Demuth , C , Sorensen , B S , Johansen , J S , Nielsen , D , Pallisgaard , N , Hoegdall , E , Pfeiffer , P & Vittrup Jensen , B 2018 , ' Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer ' , Tumor Biology , vol. 40 , no. 11 , 1010428318811207 .

Témy: Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Biomarkers, Tumor/analysis, C-Reactive Protein/metabolism, Carcinoembryonic Antigen/metabolism, Case-Control Studies, Cell-Free Nucleic Acids/analysis, Cetuximab/administration & dosage, Cohort Studies, Colorectal Neoplasms/drug therapy, Denmark, Everolimus/administration & dosage, Female, Follow-Up Studies, Humans, Irinotecan/administration & dosage, Liver Neoplasms/drug therapy, Male, Middle Aged, Prognosis, Survival Rate, Young Adult, article

URL: https://researchprofiles.ku.dk/da/publications/total-cellfree-dna-carcinoembryonic-antigen-and-creactive-protein-for-assessment-of-prognosis-in-patients-with-metastatic-colorectal-cancer(238188af-b58e-473b-8488-2981e48e31ff).html
https://doi.org/10.1177/1010428318811207
https://curis.ku.dk/ws/files/218615085/1010428318811207.pdf